Deborah Mortensen

USPTO Granted Patents = 21 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 11.6

ph-index = 10

Forward Citations = 331(Granted Patents)

Company Filing History:

20 out of 169

Signal Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404239 - Modulators of BCL6 as ligand directed degraders (2025-09-02),

2. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),

3. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),

4. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),

5. 9783505 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2017-10-10),

6. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),

7. 9557338 - Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity (2017-01-31),

8. 9556126 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2017-01-31),

9. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),

10. 9156798 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2015-10-13),

11. 9155736 - Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity (2015-10-13),

12. 9079900 - Methods of synthesis and purification of heteroaryl compounds (2015-07-14),

13. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),

14. 8569494 - Methods of synthesis and purification of heteroaryl compounds (2013-10-29),

15. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway (2013-08-13),

Title: Deborah Mortensen: Innovator in mTOR Kinase Inhibitors

Introduction

Deborah Mortensen is a prominent inventor based in San Diego, CA, who has made significant contributions to the field of medicinal chemistry. With an impressive portfolio of 20 patents, her work primarily focuses on developing innovative compounds for various therapeutic applications.

Latest Patents

Among her latest patents, Deborah has developed substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors. These patents detail heteroaryl compounds with unique structures and outline methods for preparing these critical compounds, which are essential in the fight against various diseases. The methodologies involve contacting specific compounds to achieve the desired therapeutic effects, thereby advancing the field of oncology and related medical treatments.

Career Highlights

Deborah currently works at Signal Pharmaceuticals, Inc., where she plays a vital role in research and development. Her career at this innovative company has been marked by a dedication to discovering new treatments that address unmet medical needs. Her expertise in chemical synthesis and drug development has made her a key figure in the advancement of cutting-edge pharmaceuticals.

Collaborations

Throughout her career, Deborah has collaborated with esteemed colleagues, including John J. Sapienza and Patrick Papa. Together, they have combined their expertise to push the boundaries of pharmaceutical research, resulting in groundbreaking innovations that have far-reaching implications in the healthcare industry.

Conclusion

In conclusion, Deborah Mortensen stands out as a leading inventor in the realm of mTOR kinase inhibitors, with a strong track record of patents and collaborations. Her work at Signal Pharmaceuticals, Inc. and her partnerships with other industry experts exemplify her commitment to advancing medical science and improving patient care through innovative drug discovery.

This text is generated by artificial intelligence and may not be accurate.